

Spontaneous Intracerebral Hemorrhage

Tracy Wheeler, AGACNP-BC


Advanced Spine and Brain Center





Objectives

- ▶ Etiology
- ▶ Initial management, prehospital and ED including imaging
- ▶ Treatment including management of hypertension, reversal of AC, avoidance of secondary injury, and importance of nursing cares
- ▶ Management of intracranial hypertension
- ▶ Rehab
- ▶ Case Study




What is nontraumatic spontaneous intracranial hemorrhage

- ▶ Blood accumulation within the brain parenchyma
- ▶ Second leading type of stroke
- ▶ Global burden is higher than ischemic (death and disability)
- ▶ Several etiologies, including hypertension, cerebral amyloid angiopathy, and vascular causes

Etiologies

- Hypertension (arteriolosclerosis)
- Cerebral amyloid angiopathy
- Vascular- AVM, DAV, Aneurysm
- Others- hemorrhagic infarct, tumor, sepsis, moyamoya, etc..

(Greenberg et al., 2022) (Hemphill et al., 2015)




Hypertension

- ▶ Most common cause
- ▶ Hypertensive- typically associated with the blood vessels which feed off the major cerebral arteries (90 angle)- feeding pons, midbrain, and thalamus



Cerebral Amyloid Angiopathy

- ▶ older patients with **lobar** hemorrhage
- ▶ CAA- amyloid tissue deposits on vessel wall and weakens the vessel
- ▶ Can distinguish CAA vs hypertensive in older person by location



Signs and Symptoms of ICH

- Impossible to determine hemorrhagic vs ischemic (without imaging)
- Based on size and location
- Symptoms typically associated with ICH (rapidly progressing)
 - Vomiting
 - SBP >220
 - Severe headache
 - Coma, decreased LOC



Prehospital management

- Very important- 20% decline in the time between EMS and ED evaluation
- Early treatment → improve long term outcomes
- Primary goal- Airway management, CV support, and transport
- Secondary goal- focused history including timeline, medical history, and medication history
- Notify hospital in advance

(Greenberg et al., 2022) (Hemphill et al., 2015)



Evaluation

➤ History

- Time and characteristics of symptoms
- Risk factors?
- Meds
- Recent surgery/trauma
- Illicit drugs
- Liver disease
- Kidney disease
- Diabetes



Evaluation

➤ P/E

➤ VS

➤ Neurological exam- NIHSS, NIHf,

GCS

➤ Baseline severity score (ICH score)

| | |
|---|--|
| 1a—Level of consciousness | 0 = Alert; keenly responsive 1 = Not alert, but arousable by minor stimulation 2 = Not alert; requires repeated stimulation 3 = Unresponsive or responds only with reflex |
| 1b—Level of consciousness questions: What is your age? What is the month? | 0 = Answers two questions correctly 1 = Answers one question correctly 2 = Answers neither questions correctly |
| 1c—Level of consciousness commands: Open and close your eyes Grip and release your hand | 0 = Performs both tasks correctly 1 = Performs one task correctly 2 = Performs neither task correctly |
| 2—Best gaze | 0 = Normal 1 = Partial gaze palsy 2 = Forced deviation |
| 3—Visual | 0 = No visual lost 1 = Partial hemianopia 2 = Complete hemianopia 3 = Bilateral hemianopia |
| 4—Facial palsy | 0 = Normal symmetric movements 1 = Minor paralysis 2 = Partial paralysis 3 = Complete paralysis of one or both sides |
| 5—Motor arm Left arm Right arm | 0 = No drift 1 = Drift 2 = Some effort against gravity 3 = No effort against gravity 4 = No movement |
| 6—Motor leg Left leg Right leg | 0 = No drift 1 = Drift 2 = Some effort against gravity 3 = No effort against gravity 4 = No movement |
| 7—Limb ataxia | 0 = Absent 1 = Present in one limb 2 = Present in two limbs |
| 8—Sensory | 0 = Normal; no sensory loss 1 = Mild-to-moderate sensory loss 2 = Severe-to-total sensory loss |
| 9—Best language | 0 = No aphasia; normal 1 = Mild-to-moderate aphasia 2 = Severe aphasia 3 = Mute; global aphasia |
| 10—Dysarthria | 0 = Normal 1 = Mild-to-moderate dysarthria 2 = Severe dysarthria |
| 11—Extinction and inattention | 0 = No abnormality 1 = Visual, tactile, auditory, spatial, or personal inattention 2 = Profound hemi-inattention or extinction |
| Score = 0–42 | |

Severity Score- ICH score

Communication tool and grading scale to evaluate for 30 day mortality

- GCS
- ICH Volume
- IVH
- Location
- Age

Intracerebral Haemorrhage

ICH Score (Hemphill et al.)

| Feature | Finding | Points |
|------------------------|----------------|------------|
| GCS | 3-4 | 2 |
| | 5-12 | 1 |
| | 13-15 | 0 |
| Age | ≥80 | 1 |
| | <80 | 0 |
| Location | Infratentorial | 1 |
| | Supratentorial | 0 |
| ICH volume | ≥30cc | 1 |
| | <30cc | 0 |
| Intraventricular Blood | Yes | 1 |
| | No | 0 |
| ICH SCORE | | 0-6 points |

| ICH Score | 30 Day Mortality |
|-----------|------------------|
| 0 | 0% |
| 1 | 13% |
| 2 | 26% |
| 3 | 72% |
| 4 | 97% |
| 5 | 100% |
| 6 | 100% |



Evaluation



Labs

COAGS

CBC

Kidney function tests

Glucose

Cardiac markers

UA/culture


(Greenberg et al., 2022) (Hemphill et al., 2015)

Imaging

- ▶ CT head wo- gold standard (quick, high sensitivity)
- ▶ MRI
- ▶ CTA, MRA- evaluate for vascular cause,
- ▶ spot sign with increased risk of HE and worsening outcomes
 - ▶ Aneurysm
 - ▶ AVM
 - ▶ Catheter angiogram if high suspicion for vascular cause

(Rordorf & McDonald, 2022)

(Greenberg et al., 2022) (Hemphill et al., 2015)





Treatment

- ▶ **Treat hypertension**
 - ▶ Reverse coagulopathy
 - ▶ Prevent hematoma expansion and secondary brain injury or complications
-
- ▶ Corrected INR and SBP < 160 within 4 hours has shown reduced rates of hematoma expansion (Hemphill et al., 2015)



BP management

- VERY IMPORTANT to improve outcomes and reduces hematoma expansion!
- Presenting SBP 150-220, safe to lower to SBP 130-140 (<130 can be harmful)
(Greenberg et al., 2022)
- Smooth reduction of BP- Nicardipine infusion
- **It is safe to reduce SBP to 140 in patients who presented with SBP 150-220 (Class IA evidence) (Interact2 study)- improved outcomes and QOL**

(Hemphill et al., 2015)



Reversal of AC

- **Warfarin**- vitamin K, 4 factor PCC (kcentra), FFP
For warfarin induced: Kcentra and Vit K d/t transient nature of PCC
- **Pradaxa**- Praxbind, PCC, HD (if praxbind not available)
- **Xarelto, Eliquis** – Andexxa, Kcentra (4 factor activated PCC)- ongoing studies
- **Heparin**- Protamine
- **Plavix**- DDAVP (Don't give platelets unless going to surgery- 1 unit, PATCH trial)

(Greenberg et al., 2022) (Rordorf & McDonald, 2022)



Preventing secondary injury & hematoma expansion

- ▶ Hematoma expansion occurs in up 1/3 of ICH- poor function outcome
- ▶ HE independent predictor of poor outcomes (Rordorf & McDonald, 2022)
- ▶ Increased glucose → Increased mortality and poor outcomes
 - ▶ Avoid hyper and hypo-glycemia
- ▶ Treat fever (prolonged fever leads to worse outcomes, could relate to hematoma growth)
 - ▶ r/o infectious causes
- ▶ Seizure
 - ▶ Treat if patient has a seizure
 - ▶ Altered mental status + EEG findings- AED
 - ▶ Decreased MS out of proportion- continuous EEG
 - ▶ No prophylactic AED

(Hemphill et al., 2015)



DVT prophylaxis

- ▶ SCD (compression stockings are not adequate)
- ▶ Early mobility
- ▶ After documented stable CT, may start SQ heparin or Lov enox on PBD 1-4
- ▶ Known symptomatic DVT/PE- heparin gtt vs IVC filter

(Hemphill et al., 2015)



Medical complications

- Pneumonia
- Aspiration
- Respiratory failure
- PE
- Sepsis
- Heart failure- MI, stress induced cardiomyopathy, etc

Formal dysphagia screen

ECG and cardiac markers after ICH

- 50 % of deaths after stroke attributed to these medical complications, with increase mortality (Hemphill et al., 2015)

Nursing Care

- ▶ ICU
- ▶ Frequent monitoring and exams
- ▶ Protocols for treatment of ICP, BP, fever, and glucose
- ▶ Positioning, early mobilization, and oral care
- ▶ Nurses care for ICH should be trained in GCS, NIHSS



DNR

- Discuss after 2nd full hospital day
- Self fulfilling prophecy
- Unless patient already has DNR status, and this should not decrease medical cares
- Reiterated in the recent 2022 guidelines


(Hemphill et al., 2015)



"My name is Daniel Nathan Reed. I don't initial anything."

ICP

- Monroe Kelly Doctrine
- Brain parenchyma (80%), CSF (10%), Blood (10%) in a rigid compartment. Increase in 1 component must have a decrease in the another.
- Body will compensate for a period of time, then ICP will rise (Blood, CSF, or brain will displace)
- Normal ICP 5-15, >20 elevated
- $CPP = MAP - ICP$



S/S elevated ICP

- Mental status change
- N/V/Headache
- Noted on bedside monitor 😊
- Pupillary changes
- Posturing
- Cushings triad





Treatment for ICP

▶ Nursing cares, VERY IMPORTANT

Elevate HOB

Neck straight alignment

Check cervical collar

Reduce pain/anxiety

Prevent shivering

Treat fever

Neurosurgical intervention


Mannitol, Hypertonic saline

ICP monitor: EVD vs Bolt

Decompressive craniectomy

When to measure ICP


- ▶ EVD for treatment of hydrocephalus
With decreased LOC (IIA evidence)
- ▶ GCS < 8
- ▶ Herniation
- ▶ Patients with intraventricular hemorrhage may benefit from intraventricular TPA. (Greenberg et al., 2022)



Surgery- When to operate

- ▶ **Hemorrhage removal is a life saving procedure.**
- ▶ **Generally not found to improve long-term functional outcomes**
- ▶ For supratentorial hemorrhage-
 - ▶ For nontraumatic- not generally recommended
 - ▶ STICH I- Will surgery improve mortality and functional outcomes?
 - ▶ STICH II- What if it's superficial?
 - ▶ STICH I, STICH II, and MISTIE- no clear data that outcomes improve with surgery, can be considered "life saving"
 - ▶ DC – again, not well studied

(Greenberg et al., 2022)





Surgery- When to operate

- ▶ Posterior Fossa
 - ▶ > 15cc (Greenberg et al., 2022)
 - ▶ Worsening neuro exam
 - ▶ Hydrocephalus from obstruction
 - ▶ Brainstem compression



Prevention of Recurrent ICH

- ▶ Review patient specific risk factors
- ▶ SBP < 130/80- modify BP immediately after bleed (Selim, 2022)
- ▶ Etoh < 2 drinks/day, no illicit drugs, tobacco use
- ▶ Treat OSA
- ▶ Resume AC uncertain, wait 4-8 weeks in patients w/o mechanical heart valves. Aspirin can be started following days, IF needed. Antiplatelet w/ valve may be started after stable CT head. (Selim, 2022)

Rehab

- Multidisciplinary rehab
- Reasonable to start within 24-48, NOT first 24 hours
- Continue rehab into a community program
- Monitor closely for depression (Greenberg et al., 2022)





Case Study

- ▶ 49-year-old male presented via EMS after being found down by his wife
- ▶ PMH: hypertension- untreated, no PCP
- ▶ Meds: No prescription medications, multiple supplements and diet pills


Initial presentation- Obtunded, moving the left arm and leg spontaneously, densely plegic on the right. Sonorous respirations with apnea.



Case Study: Evaluation


- ▶ Exam: VS: BP 214/131. Initial NIHSS 25, GCS 8. Densey plegic on left.
- ▶ Labs (p): INR 1.1
- ▶ CT: large left basal ganglia ICH measuring 6.3 cm x 2.6 cm, significant mass-effect and effacement of the left lateral ventricle, 1 cm left on right.
- ▶ ICH score: 2 - estimated 30 day mortality of 26%

Case Study: Evaluation



Case Study: Treatment


- ▶ Cardene infusion to keep SBP <140
- ▶ Intubated for airway protection
- ▶ Taken emergently to the OR for decompressive craniectomy





Case Study: ICU care

- ▶ Hourly neuro checks
- ▶ Hypertonic saline, sodium goal 145-150
- ▶ Cardene infusion for SBP <140
- ▶ Oral Norvasc initiated
- ▶ POD 2- extubated
- ▶ Exam- Aphasic, facial droop, densely plegic on right
- ▶ Complication with external hydrocephalus required an LP shunt
- ▶ Ultimately dc'd to rehab.
- ▶ 6 month follow up- remained densely plegic, but at home and remaining mobile with wheelchair



References

- DeSimone, C., Graff-Radford, J., El-Harasis, M., Rabinstein, A., Asirvatham, S., Jolmes, D., (2017). Cerebral Amyloid Angiopathy: Diagnosis, clinical implications, and management strategies in atrial fibrillation. *Journal of the American College of Cardiology*, 17,9, pages 1173-1182.
- Freeman, D.W., Weitz, J. (2020). Reversal of anticoagulation in intracranial hemorrhage. *UpToDate*. Retrieved 6/19/20 from <https://www.uptodate.com/contents/reversal-of-anticoagulation-in-intracranial-hemorrhage?source=autocomplete&index=0~2&search=reversal%20of%20ant>.
- Greenberg, S. (2020). Cerebral amyloid angiopathy, *UpToDate*. Retrieved 6/22/2020 from https://www.uptodate.com/contents/cerebral-amyloid-angiopathy?search=cerebral%20amyloid%20angiopathy&source=search_result&selectedTitle=1~27&usage_type=default&display_rank=1
- Greenberg, S. M., Ziai, W. C., Cordonnier, C., Dowlatshahi, D., Francis, B., Goldstein, J. N., Hemphill, J. C., Johnson, R., Keigher, K. M., Mack, W. J., Mocco, J., Newton, E. J., Ruff, I. M., Sansing, L. H., Schulman, S., Selim, M. H., Sheth, K. N., Sprigg, N., & Sunnerhagen, K. S. (2022). 2022 guideline for the management of patients with spontaneous intracerebral hemorrhage: A guideline from the American Heart Association/American Stroke Association. *Stroke*, 53(7). <https://doi.org/10.1161/str.0000000000000407>
- Hemphill, J.C., Bonovich, D.C., Besmertis, L., Manley, G.T., Johnston, S.C. (2001). The ICH Score: A Simple Reliable Grading Scale for Intracerebral Hemorrhage. *Stroke*, 32, 891-897.
- Hemphill, J.C., Greenberg, S.M., Anderson, C.S., Bendok, B., Cushman, M., Fung, C., Goldstein, J.N., ... Council on Clinical Cardiology (2015). *Stroke*, 2015, 46, pages 2032-2060.
- Hemphill, J. C., Greenberg, S. M., Anderson, C. S., Becker, K., Bendok, B. R., Cushman, M., Fung, G. L., Goldstein, J. N., Macdonald, R. L., Mitchell, P. H., Scott, P. A., Selim, M. H., & Woo, D. (2015). Guidelines for the management of spontaneous intracerebral hemorrhage. *Stroke*, 46(7), 2032–2060. <https://doi.org/10.1161/str.0000000000000069>
- NEJM Journal Watch: Summaries of and commentary on original medical and scientific articles from key medical journals. (n.d.). Retrieved November 3, 2022, from <https://www.jwatch.org/na54975/2022/06/17/intracerebral-hemorrhage-guidelines-2022-key-new-aspects>
- Rordorf, G and McDonald C. (2020) Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis. *UpToDate*. Retrieved 4/6/20 from <https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-pathogenesis-clinical-features-and-diagnosis?source=autocomplete&index=1~2&search=spontaneous%20intracerebral#references>
- Rordorf, G and McDonald C. (2020) Spontaneous intracerebral hemorrhage: Treatment and prognosis. *UpToDate*. Retrieved 4/6/20 from https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-treatment-and-prognosis?search=spontaneous%20intracerebral&topicRef=1133&source=related_link



References

- Rordorf, G & McDonald, C. (2022). Spontaneous intracerebral hemorrhage: Acute treatment and prognosis. *Up-to-date*. Retrieved November 3, 2022 from [Spontaneous intracerebral hemorrhage: Acute treatment and prognosis - UpToDate](#)
- Selim, M (2022). Spontaneous intracerebral hemorrhage: Secondary prevention and long-term prognosis up-to-date. Retrieved November 3, 2022 from [Spontaneous intracerebral hemorrhage: Secondary prevention and long-term prognosis - UpToDate](#)
- Rordorf, G & McDonald, C. (2022). Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, diagnosis. *Up-to-date*. Retrieved November 3, 2022 from [Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis - UpToDate](#)